{"id":7865,"date":"2026-06-12T11:51:46","date_gmt":"2026-06-12T15:51:46","guid":{"rendered":"https:\/\/cqdm.org\/?post_type=project&#038;p=7865"},"modified":"2026-06-16T16:10:49","modified_gmt":"2026-06-16T20:10:49","slug":"g-protein-coupled-receptors-precision-pharmacology-for-the-treatment-of-idiopathic-pulmonary-fibrosis","status":"publish","type":"project","link":"https:\/\/cqdm.org\/en\/achievement\/funded-projects\/g-protein-coupled-receptors-precision-pharmacology-for-the-treatment-of-idiopathic-pulmonary-fibrosis\/","title":{"rendered":"G protein-coupled receptors precision pharmacology for the treatment of idiopathic pulmonary fibrosis"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-7387b849 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p class=\"is-style-suptitle wp-block-paragraph\">Principal Investigator<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong><strong>Michel Bouvier<\/strong><\/strong><br>Universit\u00e9 de Montr\u00e9al<br><\/p>\n<\/div>\n<\/div>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" id=\"block-f144a6d1-0fff-4954-bbb0-b6887311b986\"\/>\n\n\n\n<p class=\"is-style-intro wp-block-paragraph\" id=\"block-0b024f00-3d65-4535-9656-7964e0bd141d\">Project of $1,082,323 over 2 year<\/p>\n\n\n\n<ul class=\"wp-block-list is-style-checkmark\">\n<li><strong>Supported by CQDM through:<\/strong><br>Minist\u00e8re de l\u2019\u00c9conomie, de l\u2019Innovation et de l\u2019\u00c9nergie du Qu\u00e9bec (MEIE)<\/li>\n\n\n\n<li><strong>And by co-funding partner:<\/strong><br>&#8211; Drave Therapeutics and Universit\u00e9 de Montr\u00e9al<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" id=\"block-22757ac3-7e91-4e37-97af-3f8b9f955d83\"\/>\n\n\n\n<h2 id=\"block-c24b9fa8-8b68-4be5-940f-0f03a6109871\" class=\"wp-block-heading\">The project in detail:<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Challenge<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-ff7da0e8-a888-49f9-87ee-d6876dc4fcc6\">Despite recent encouraging progress, Idiopathic Pulmonary Fibrosis (IPF) remains a disease with unmet medical needs. To date, no approved drugs significantly change the course of the pathology. The two approved drugs, pirfenidone and nintedanib, only slow fibrosis progression but do not halt or reverse the course of the disease. A handful of drugs targeting this disease are in different phases of clinical trials. Yet, as for all chronic diseases, multipronged therapeutic approaches exploiting different mechanisms of action will likely be required to fully address the needs of IPF patients.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Solution<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-ff7da0e8-a888-49f9-87ee-d6876dc4fcc6\">Using the team\u2019s knowledge of G protein-coupled receptor (GPCR) signaling properties that are known to be involved in the pulmonary fibrosis and regenerative processes, they will identify molecules that control the signalling of these GPCRs in a therapeutically relevant manner, combining anti-fibrotic properties with proregenerative effects. For this purpose, the signaling profiles of molecules already identified by the Drug Discovery Unit of IRIC will be established, and a medicinal chemistry campaign pursued to identify compounds with proper signaling profile and drug-like pharmacokinetics properties.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Expected Achievements \/Impacts<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\" id=\"block-ff7da0e8-a888-49f9-87ee-d6876dc4fcc6\">The team expect to identify molecules that have the proper signaling profile for GPCRs involved in IPF. Following the in vitro characterization of these molecules, the demonstration of in vivo activity in pre-clinical models of IPF will represent a major inflection point in the development of a new therapy. In addition to lead to the generation of novel intellectual property, these molecules will represent drug candidates for further development by Drave Therapeutics, a newly created Quebec-based biotechnology company. The deployment of the project will allow creation of new jobs and retention of highly qualified personal. Together, these will have positive impacts on Quebec economy, in addition to potentially offer early access to new therapies to Quebec patients resulting from the clinical trial that should ensue.<\/p>\n","protected":false},"featured_media":3830,"template":"","project-category":[96],"class_list":["post-7865","project","type-project","status-publish","has-post-thumbnail","hentry","project-category-small-molecules"],"acf":[],"_links":{"self":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project\/7865","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/types\/project"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media\/3830"}],"wp:attachment":[{"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/media?parent=7865"}],"wp:term":[{"taxonomy":"project-category","embeddable":true,"href":"https:\/\/cqdm.org\/en\/wp-json\/wp\/v2\/project-category?post=7865"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}